Clinical implications of PNA‑sequencing as a complementary test for EGFR mutation analysis in human lung cancer

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the first-line regimen for the treatment of non-small cell lung cancer (NSCLC) patients with EGFR mutations. However, false-negative results are occasionally observed, even with FDA-approved molecular tests. Such examples in...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yi-Lin, Lin, Chien-Chung, Yu, Yu-Ting, Chen, Wan-Li, Yang, Shu-Ching, Huang, Wenya, Su, Wu-Chou, Chow, Nan-Haw, Ho, Chung-Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10655035/
https://www.ncbi.nlm.nih.gov/pubmed/38020305
http://dx.doi.org/10.3892/ol.2023.14126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10655035/
https://www.ncbi.nlm.nih.gov/pubmed/38020305
http://dx.doi.org/10.3892/ol.2023.14126

Ejemplares similares